Acta Europ Fertil 1992;23:221-4
Some users have even reported reduced cravings for alcohol and other compulsive behaviors, pointing to GLP-1's effects on the brain's reward circuitry
Here are a few ways future formulations could shift the market: Oral (Rybelsus 2.0, better semaglutide formulations) What changes: Easier to prescribe and adhere to, but worse tolerability Where it moves: Into primary care lower friction, tighter payer control Strategic shift: More access, same adherence problem Risk: Higher churn, more side-effect driven dropout Next-gen combos (e.g., GLP-1 + GIP + amylin, muscle-sparing) What changes: Better outcomes, better tolerability Where it moves : Into specialist-aligned care models deeper payer integration Strategic shift: Drugs become platforms unlock long-term value Risk: Slow coverage without strong RWE
Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy
The licensed options now also include an oral GLP-1 medicine
What potential risks worry you the most
